TREATMENT FOR HEMOPHILIA A WITH FACTOR VIII INHIBITORS
Hemlibra is approved by the Food and Drug Administration (FDA) as routine prophylaxis in children and adults with hemophilia A and factor VIII inhibitors. The technical name of Hemlibra is Emicizumab-kxwh.
Hemlibra is a biologic drug - a genetically engineered antibody, or protein used by the immune system to identify and neutralize substances. Hemlibra is believed to work by connecting factors IXa and X, proteins that, when brought together, activate the coagulation cascade process and allow blood to clot.
How do I take it?
Prescribing information states that Hemlibra is given as a subcutaneous injection once weekly.
Hemlibra comes in the form of a single-use vial.
The FDA-approved label for Hemlibra lists common side effects including headache, joint pain, and injection site reactions.
Rare but serious side effects listed for Hemlibra include thrombotic microangiopathy and thromboembolism, conditions in which potentially fatal blood clots form.
For more details about this treatment, visit:
Hemlibra - Genentech